Alzheimer's disease

On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Eisai
Biogen
Alzheimer's disease
FDA
Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Alzheimer's disease
drug pricing
Medicare
Biogen
Eisai
Leqembi
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Eisai
Biogen
Leqembi
Alzheimer's disease
South Korea
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Alzheimer's disease
FDA
insurance
Leqembia
Biogen
Eisai
Eli Lilly
donanemab
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
FDA
Biogen
Eisai
Alzheimer's disease
Leqembi
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Medicare
Alzheimer's disease
Eisai
Biogen
Leqembi
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Alzheimer's disease
patients
clinical trials
Biogen
Eisai
Eli Lilly
Alzheimer’s disease market expected to reach $13.7bn across the 8MM by 2030
Clinical Trials Arena
Wed, 05/31/23 - 10:53 am
Alzheimer's disease
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Wed, 05/24/23 - 06:51 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Thu, 05/11/23 - 11:14 am
Eli Lilly
donanemab
Alzheimer's disease
physicians
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Thu, 05/4/23 - 10:27 am
Eli Lilly
Alzheimer's disease
donanemab
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
Stat
Wed, 05/3/23 - 10:39 pm
Eli Lilly
Alzheimer's disease
Daniel Skovronsky
Lilly drug slows Alzheimer’s decline in large study
BioPharma Dive
Wed, 05/3/23 - 11:54 am
Eli Lilly
donanemab
clinical trials
Alzheimer's disease
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Fri, 04/28/23 - 10:08 am
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Wed, 04/26/23 - 09:59 am
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs
Reuters
Fri, 04/21/23 - 10:24 am
Eli Lilly
Medicare
Alzheimer's disease
Leqembi
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Sun, 04/16/23 - 11:17 pm
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA

Pages